CENTER FOR DISEASE CONTROL

Morbidity and Mortality

Vol. 19, No. 34

WEEKLY
REPORT

For Week Ending August 29, 1970

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE / PUBLIC HEALTH SERVICE / HEALTH SERVICES AND MENTAL HEALTH ADMINISTRATION

DATE OF RELEASE: SEPTEMBER 4, 1970 - ATLANTA, GEORGIA 30333

EPIDEMIOLOGIC NOTES AND REPORTS TRANSFUSION-INDUCED MALARIA — Maryland

On July 24, 1970, a 28-year-old man was transferred to a hospital in Baltimore, Maryland, for treatment of hypertension resulting from chronic renal disease. He began peritoneal dialysis on July 25 and on that day was given two units of whole blood. Subsequently hemodialysis was initiated, and he received two additional transfusions, one each on August 5 and August 8.

On August 5 he began to have spiking temperature elevations to 104°F. and chills. A massive pericardial effusion was tapped on August 13, from which an *Escherichia* species was cultured. On August 17 another pericardicentesis was performed and parasitic ring forms were detected in 5 percent of the red blood cells of the effusion; they were tentatively identified as *Plasmodium falciparum*.

On review of previous peripheral smears, parasites were found on smears obtained as early as August 11. Treatment was begun with oral quinine and pyrimethamine.

The patient denied recent travel to a malarious area, history of malaria or unexplained febrile illness, and the (Continued on page 334)

TABLE I. CASES OF SPECIFIED NOTIFIABLE DISEASES: UNITED STATES (Cumulative totals include revised and delayed reports through previous weeks)

	34th WE	EK ENDED		CUMULA'	CUMULATIVE, FIRST 34 WEEKS			
DISEASE	August 29, August 23, 1970 1969		MEDIAN 1965 - 1969	1970	1969	MEDIAN 1965 - 1969		
Aseptic meningitis	302	141	141	2,489	1,559	1,510		
delinsis	3	3	7	133	145	156		
Encephalitis, primary:	28	6	2	244	101	101		
Arthropod-horne & unspecified	35	26	48	849	693	974		
-incephalitis nost-infectious	6	10	10	305	231	521		
Palitis seriim	167	109	783	4,730	3,445	26,348		
	1,173	880	Į.	36,487	30,326	O.		
	62	66	33	2,239	1,801	1,276		
otes (tilbeola)	186	146	175	39,235	20,001	57,254		
"" INFOCOCCAL infections total	37	30	31	1,808	2,300	2,248		
- villan	36	29	31	1,624	2,097	2,068		
"IIIIATV	1	1	1	184	203	180		
	620	504		74,476	66,989	• • •		
Only entries for all	_	1	1 1	18	11	37		
	-	1	-	18	11	33		
	201	322		48,786	48.364			
	2	-	3	75	94	110		
	3	2	5	94	92	118		
	11	5	7	183	182	236		
	12	15	13	273	339	209		
Rables in animals	53	53	74	2,047	2,367	2,846		

TABLE II. NOTIFIABLE DISEASES OF LOW FREQUENCY

Anthrax:	Cum.	Psittacosis: Calif1	44
Leprosy: Calif4, La1, Mich1 Leptospirosis: Calif1, Tex2 Plague: N. Mex1	9 86	Rabies in Man:	44 65

MALARIA - (Continued from front page)

use of commonly-shared syringes. The donors of the four units of blood he received were identified. Three previously donated blood to a blood collection service in North Carolina. Each of the three denied foreign travel and two had donated blood previously without incident, therefore they were considered unlikely as the source of infection. The fourth unit was donated on July 22 at a collection center in Columbia, South Carolina, by a 21-year-old serviceman and was given to the patient on July 25. This donor denied travel to a malarious area when the blood was collected, but a check of his Army records revealed that he had returned from Vietnam on Oct. 16, 1969. Upon repeat questioning, he denied having malaria or any febrile illness while in Vietnam or after his return, and he stated that he took all of his antimalarial prophylactic drugs as required. A peripheral blood smear obtained on August 18 demonstrated rare parasites of P. falciparum. The end-point dilutions of his serum when tested with the indirect fluorescent antibody (IFA) test for malaria were P. falciparum 1:256, P. vivax 1:64, and P. malariae 1:64. Peripheral blood smears and sera for IFA testing are being obtained from the remaining three donors.

(Reported by Patricia McIntyre, M.D., Attending Physician, Duane Smith, M.D., Fellow in Infectious Diseases, Alfred Grindon, M.D., Director, Blood Bank, Johns Hopkins Hospital School of Medicine; and Howard Garber, M.D., State Epidemiologist, Maryland.)

Editorial Note:

This is the fifth case of transfusion-induced malaria reported to the Malaria Surveillance Unit, CDC, in 1970. Twenty-one cases have been reported since 1966 when large numbers of troops began to return from Vietnam, and the infective donor in at least 10 cases was shown to be a Vietnam returnee.

ZINC POISONING FROM LEMONADE - Bellevue, Washington

On July 14, 1970, in Bellevue, Washington, two of five members of a Washington State highway survey team developed symptoms subsequently identified as resulting from ingestion of lemonade contaminated with zinc. They drank lemonade from a portable, 2-gal., galvanized water cooler. Investigation was begun by the health department when a private physician reported giving medical attention to one of the two ill men.

Lemonade was prepared in the galvanized cooler at 5:30 a.m. on July 14. Five packages of powdered lemonade and three cups of sugar were mixed in 2 gallons of water. The lemonade drink was consumed the same day between 10 a.m. and 4 p.m. by the five crew members. Three of the crew members drank only one to three cups of lemonade because it tasted peculiar. They ate their lunch and had no apparent symptoms. The two men who became ill in the afternoon, one 33 years old and the other 27 years old, ate no lunch but drank most of the lemonade. Both men stated that their saliva seemed to thicken in their mouth as they drank each cup. As a result, they became thirstier and drank more lemonade.

The 33-year-old man became ill at 3 p.m. while at work, with lightheadedness, nausea, and abdominal pain followed by diarrhea. He suspected poisoning from the lemonade when he removed the plastic-lined lid and noticed that the interior of the cooler was galvanized and showed extensive corrosion. He drove immediately to his physician who induced vomiting. The following morning, he returned

to work feeling weak and complaining of an upset stomach. The 27-year-old man became ill at 4 p.m. on his way home, experiencing severe abdominal pain and diarrhea. The following day, he stayed home from work, convinced that he had suddenly developed ulcers. Both men recovered within a few days.

A 1-oz. sample of lemonade, remaining in the cooler, was analyzed by x-ray spectrometry. Concentration of zinc in the liquid sample was found to be approximately 2.2 parts per thousand by weight (mg/ml).

The 2-gal. cooler is made by a company in Houston, Texas, that produces both a galvanized and a plastic-lined can. This type of water cooler is in common use by men who work out-of-doors for carrying drinking water. The company was notified of this episode. It was suggested that a precautionary note be enclosed in their galvanized water cooler to reserve its use for water alone.

Appropriate action was immediately initiated by local and state authorities to prevent a recurrence of zinc poisoning from misuse of galvanized water coolers among workers in Washington.

(Reported by Richard Rowley Sefi, M.D., Private Physician, Seattle; Herb W. Anderson, Environmental Epidemiologist, Fred Aldridge, Director of Sanitation, and Donald R. Peterson, M.D., Director of Epidemiology, Seattle-King County Department of Public Health; and Byron J. Francis, M.D., Supervisor, Epidemiology Section, Division of Health, Washington State Department of Social and Health Services.)

SURVEILLANCE SUMMARY RUBELLA - United States

In January 1966, rubella was officially added to the list of notifiable diseases by the Conference of State and Territorial Epidemiologists. Before this, some states maintained rubella surveillance and optionally reported cases to the Center for Disease Control. The data since 1966 have been submitted to the CDC in the Weekly Telegraphic Report of Notifiable Diseases.

There exists, at present, considerable variability in the completeness of rubella reporting, as well as in the type and accuracy of the information reported. The variability and the potential bias due to use of data collected from selected areas demand that surveillance data be interpreted with some caution.


Rubella incidence since 1928 in 10 selected areas is presented in Figure 1. Although the incidence varies considerably, these data suggest that major epidemics occurred throughout the United States in 1935, 1943, and 1964. Further, high incidence was reported in 1952 and 1958. These periods of increased rubella activity occurred at 6- to 9-year intervals.

Reported cases of rubella for the 10 years 1960-1969 were also inconsistent and sporadic (Table 1). The reported cases by month of onset since January 1963 for 24 selected states (Figure 2) shows the seasonal variation in disease

Figure 1

RUBELLA INCIDENCE — TEN SELECTED AREAS*

UNITED STATES — 1928-1970



incidence. The number of reported cases in epidemic and nonepidemic years increased in early winter, peaked in the spring, and declined to a low point in late summer and autumn. The uniformity of the seasonal pattern of rubella in the different regions of the United States is shown in Figure 3. The pattern seen in the individual regions is similar to that noted nationally. Except in the West South Central region, no major increase in rubella activity has occurred during the current epidemiologic year compared with the past two epidemiologic years. Increased reported cases from Texas account in large measure for the high (Continued on page 337)

Figure 2
REPORTED RUBELLA CASES BY MONTH OF ONSET
24 SELECTED STATES – JANUARY 1963-AUGUST 1970




Table 1 Reported Cases of Rubella by State — 1960-1969

		Reported	Cases of	Rubella by	State —	1960-1969				
AREA	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960
UNITED STATES	55,549	48,446	46,888	46,975	100,842	448,796	60,431†	37,265	43,810	50,958
No. States Reporting		(47)	(47)	(44)	(36)	(35)	(32)	(32)	(33)	(31)
NEW ENGLAND	4,130	_								
Maine	417	629	856	421	953	7,463	953	514	1,436	1,451
New Hampshire	109	92	214	133	163	1,331	453	57	217	163
Vermont	121	91	227	130	-		-	0.700		
Massachusetts Rhode Island	1,463 289	3,608 1,397	1,429 384	2,056 283	2,839 234	37,105 11,399	11,739 1,324	3,766 129	6,443 313	5,562 138
Connecticut	1,731	3,039	1,910	2,245	1,719	40,737	3,945	1,338	2,748	3,750
	1	3,033	1,510	2,243	1,713	40,737	3,545	1,550	2,740	0,700
MIDDLE ATLANTIC New York	3, 50 5 1,996	4,389	2,258	2,631	2,505	61,624	8,158	4,246	4,465	8,816
New Jersey	627	1,680	NN NN	2,05		01,024	0,150	7,240	1 7,703	
Pennsylvania	882	208	179	114	_	_	_	_	_	_
EAST NORTH CENTRAL	12,898									
Ohio	1,320	2,099	771	1,254	2,348	19,194	2,953	979	1,607	3,621
Indiana	2,385	912	669	2,345	1,911	13,037	1,972	1,406	1,371	1,937
Illinois	1,786	3,355	1,621	2,935	4,850	29,685	2,108	2,030	3,438	1,723
Michigan	4,127	1,908	2,338	3,040	9,937	18,922	1,637	1,091	1,224	2,028
Wisconsin	3,280	2,980	3,340	5,446	9,570	96,583	4,731	4,365	5,418	4,841
WEST NORTH CENTRAL	4,088								i	
Minnesota	245	69	97	124	1,910	3,232	_	_	1	-
lowa	2,541	2,053	1,896	1,952	3,798	18,481	1,727	416	482	438
Missouri	580	142	350	61	39	573	155	158	_	_
North Dakota South Dakota	256	238	181 3	205 2		_	_	_	_	_
Nebraska	352	32	153		13	_	_	_		
Kansas	114	128	16	NN	-	_	_		_	-
SOUTH ATLANTIC	7,645									
Delaware	211	150	84	55	111	802	135	144	276	38
Maryland	865	366	615	404	248	3,583	299	258	391	211
District of Columbia	166	14	9	15	16	455	149	17	50	44
Virginia	1,598	644	675	961	_	-	_	_	_	-
West Virginia	2,417	904	639	1,037	2,091	6,774	1,438	960	748	314
North Carolina	19	-	NN	-	_	-		_	_	_
South Carolina	301	259	231 784	284 493	705	††† 497	- 85	- 315	_ 34	140
Georgia Florida	2,068	1,491	1,174	1,447	285 892	8,661	1,008	501	732	834
	1	1,431	1,174	1,447	652	0,001	1,000	301	/ / / /	001
EAST SOUTH CENTRAL Kentucky	3,156 1,187	861	2,141	1,960	1,190	18,027	2,158	914	2,034	1,696
Tennessee	1,635	1,135	1,367	2,578	','50	- 10,027		_		
Alabama	136	464	191	122	169	3,574	88	57	60	45
Mississippi	198	9	1.4.4	_	1,167	6,784		_	2	-
WEST SOUTH CENTRAL	6,504		2.000							
Arkansas	199	4	114	14	428	1,025	370	59	168	218
Louisiana	39	62	NN	_	-	-	-	-	-	-
Oklahoma	1,852	93	558	NN	_	_	-	-	_	-
Texas	4,414	2,923	640	140	_	_	_	_	-	-
MOUNTAIN	3,064									702
Montana	108	96	200	376	2,526	1 '	898	1,011	747	783 52
Idaho	94 103	130 14	72 5	119	1,088	462 25	82	116	87	- 52
Wyoming Colorado	1,423	892	1,885	785	1,973	11,817	1,219	1,729	1,803	1,549
New Mexico	312	134	309	113	272	351	109	26	41	142
Arizona	861	700	1,168	2,619	2,076	6,653	1,608	1,732	1,751	1,493
Utah	158	110	71	80	1,489	588	85	111	110	143
Nevada	5	_	425	30	22	-	-	_		-
PACIFIC	10,559		2			1				
Washington	1,943	1,851	3,377	3,435	25,258	11,119	5,526	5,152	3,176	4,230
Oregon	743	625	986	1,174	12,956	4,190	2,114	3,318	2,298	4,167
California	6,174	4,890	9,539	2,847*			1 107	450	-	331
Alaska	543	289	381	112	451	747	1,127 78	152	89 50	60
NN - Report not required	1,156	287	356	Data not a	3,345	929	L /8	198	1 50	

NN - Report not required by State Health Dept.

No cases reported.

† Includes data for Maine from State Report.

†† Hawaii not included in U.S. total.

* Vol. reports prior to 11/66.


... Data not available

ttt Included in measles.

Source: Reported Incidence of Notifiable Diseases in the United States;
Annual Supplement for respective year.

RUBELLA - (Continued from page 335)


Figure 3
RUBELLA CASE RATES BY FOUR-WEEK PERIODS
EPIDEMIOLOGIC YEARS, 1967-68; 1968-69; 1969-70



case rates calculated for the West South Central region.

The age distribution for reported cases of rubella since 1963 is shown in Table 2. Most reported cases of rubella are from the 5-9 and 10-14 year age groups; approximately 66 percent of all reported cases occurred in these two age groups. The cumulative percent of reported cases by age indicates that 80 percent of the reported cases had occurred by age 14, and 92 percent by age 20 (Figure 4). Significant numbers of cases were reported among young adults, particularly women.

Figure 4
CUMULATIVE PERCENT OF RUBELLA CASES BY AGE
GROUPS FROM SELECTED AREAS* -- 1963-1967



(Reported by the Field Services Branch, and the Office of Statistical Services, Epidemiology Program, CDC.)

A copy of the report from which these data were derived is available on request from

Center for Disease Control Attn: Chief, Field Services Branch, Epidemiology Program Atlanta, Georgia 30333

If you are on the mailing list to receive the Rubella Surveillance Report, a copy will be sent to you without an additional request.

Table 2
Reported Cases of Rubella by Age and Sex for Selected Areas — 1963-1967

4		Total			Male			Female	
Age	Number	Percent	Cumulative Percent	Number	Percent	Cumulative Percent	Number	Percent	Cumulative Percent
0-4	16,373	13.5	13.5	8,218	14.3	14.3	8,155	12.9	12.9
5-9	52,078	43.1	56.6	25,660	44.5	58.8	26,418	41.8	54.7
10-14	28,403	23.5	80.1	13,483	23.4	82.2	14,920	23.6	78.3
15-19	14,527	12.0	92.2	7,446	12.9	95.1	7,081	11.2	89.5
20-39	8,100	6.7	98.9	2,541	4.4	99.5	5,559	8.8	98.3
40+	1,363	1.1	100.0	286	0.5	100.0	1,077	1.7	100.0
Total	120,844			57,634			63,210		

RECOMMENDATION OF THE PUBLIC HEALTH SERVICE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

RUBELLA VIRUS VACCINE

INTRODUCTION

Live, attenuated rubella virus vaccine* appears to be a highly effective immunizing agent and the first suitable method of controlling rubella. Through June 1970, more than 19 million doses of vaccine have been distributed in the United States.

Rubella is generally a mild illness, but if the infection is acquired by a woman in the early months of pregnancy, it poses a direct hazard to the fetus. Preventing infection of the fetus is the principal objective of rubella control. This can best be achieved by eliminating the transmission of virus among children, who are the major source of infection for susceptible pregnant women. The live, attenuated rubella virus vaccine is safe and protective for children. Because of an undetermined risk of the vaccine virus for the fetus, the safety for pregnant women is not known.

RUBELLA

Rubella is one of the common childhood exanthems. Most cases occur in school-age children particularly during the winter and spring. By early adulthood, approximately 80 to 90 percent of individuals in the continental United States have serological evidence of immunity.

Rubella is clinically variable, and its common features, such as post-auricular and sub-occipital lymphadenopathy and transient erythematous rash, are often overlooked or misdiagnosed. A mild febrile illness may not be recognizable as rubella, and moreover, inapparent infection often occurs, which further decreases the reliability of clinical history.

Transient polyarthralgia and polyarthritis may accompany or follow the illness. Joint symptoms occur frequently in adult women but are also observed occasionally in adult men and in children.

By far the most important complication of rubella is the frequent occurrence of fetal infection when a woman acquires rubella early in pregnancy, especially in the first trimester. Other complications of rubella such as involvement of the central nervous system or thrombocytopenia are rare.

RUBELLA IMMUNITY

Immunity following rubella appears to be long lasting, even after mild illness or clinically inapparent infection. As with other viral diseases, re-exposure to natural rubella is sometimes accompanied by a booster-type antibody rise without clinical disease, indicative of asymptomatic reinfection. To date, these reinfections have not been shown to be of practical significance.

The only reliable evidence of immunity is a positive serological test. The hemagglutination-inhibition (HI) antibody determination is the test of choice for evaluating immunity. However, because of the variation among reagents and technical procedures, results of serological tests should be accepted only from laboratories of recognized competence that regularly perform these tests.

LIVE RUBELLA VIRUS VACCINE

Live rubella virus vaccine is prepared in duck embryo, dog kidney, or rabbit kidney cell cultures. It is administered as a single subcutaneous injection. Differences in the frequency of reactions as well as immunogenicity have been reported with the available rubella vaccine preparations. Approximately 95 percent of susceptible vaccinees develop antibodies. Although titers are lower than those observed following natural rubella infection, vaccination affords protection against clinical illness following natural exposure.

Antibody levels have declined very little during the 4-year period of observation of children who were among the first to be immunized with rubella vaccine. Long-term protection is likely, but its exact duration can be established only by continued observation.

Rubella-like symptoms of rash and lymphadenopathy occur occasionally after vaccination. Complaints related to the joints and distal portions of the extremities have been the most common. Arthralgia and arthritis have been reported in as many as 15 percent of vaccinated children. The small joints are most commonly involved and discomfort is most prominent at night. Less frequently, children may develop pain and paresthesias in the arms and hands or pain in the popliteal fossa with or without joint involvement. These reactions occur more frequently following use of the more immunogenic canine renal cell vaccine. These symptoms begin between 2 and 8 weeks following vaccine administration and may persist for as long as 2 weeks. Though brief recurrences have occurred, no permanent residuae have been reported. It is felt that these symptoms are consistent with manifestations of natural disease.

In susceptible women, reactions of arthralgia and arthritis are much more frequent and more likely to be severe. Not enough susceptible men have been studied to show whether they experience comparable reactions as frequently as women.

Vaccinees may shed relatively small amounts of virus from the pharynx for brief periods between the first and fourth weeks after inoculation. For this reason, transmission of vaccine virus to susceptible contacts is considered theoretically possible. In studies involving deliberate exposure of vaccinees to several thousand susceptible uninoculated persons, only a few contacts developed antibodies. Investigation of the circumstances indicated that most of these seroconversions could be accounted for by the occurrence of natural rubella or experimental error. In a few instances, seroconversion was thought to be compatible with vaccine virus transmission. However, in view of the

^{*}The official name is Rubella Virus Vaccine, Live.

sizable negative experience and the recognized background of unrelated seroconversions, it is difficult to interpret the significance of each individual report of possible vaccine virus spread. Though further documentation is necessary, the probability of such spread is exceedingly low. Thus, the potential hazard to pregnant women is considered to be of such a low order of magnitude that use of vaccine in community programs or in children whose mothers are pregnant is not contraindicated.

Vaccinees exposed to rubella often develop increases in antibody titers without clinical symptoms. These reinfections, which are more frequent in individuals with low antibody titers, occur more commonly in vaccinees than in naturally immune persons. Investigations conducted to date indicate that these reinfections are virologically abbreviated in that viremia has not been detected and virus excretion in the pharynx appears to be significantly diminished in amount and duration. There is no evidence indicating that reinfected vaccinees can transmit virus to susceptible contacts. Likewise, the absence of demonstrable viremia during reinfection suggests that women with vaccine-induced immunity if exposed to rubella during pregnancy would be unlikely to transmit virus to the fetus. However, further study is needed to document the precise clinical and epidemiologic significance of reinfection.

RECOMMENDATIONS FOR VACCINE USE

Live rubella virus vaccine is recommended for boys and girls between the age of 1 year and puberty. Vaccine should not be administered to infants less than 1 year old because of possible interference from persisting maternal rubella antibody.

In the continental United States, children in kindergarten and elementary school deserve priority for vaccination because they are commonly the major source of virus dissemination in the community. A history of rubella illness is not reliable enough to exclude children from immunization.

Vaccination of adolescent or adult males is of lower priority. The vaccine may be useful in preventing or controlling outbreaks of rubella in circumscribed population groups.

Pregnant women should not be given live rubella virus vaccine. It is not known to what extent infection of the fetus with attenuated virus might take place following vaccination, or whether damage to the fetus could result. Therefore, routine immunization of adolescent girls and adult women should not be undertaken because of the danger of inadvertently administering vaccine to pregnant women.

Women of child-bearing age may be considered for vaccination only when the possibility of pregnancy in the following 2 months is essentially nil; each case must be considered individually. This cautious approach to vaccinating postpubertal females is indicated for two reasons: First, because of the theoretical risk involved in vaccination of pregnant women; and second, because significant congenital anomalies occur in approximately 3 percent of all births, and their fortuitous appearance after vaccine had been given during pregnancy could lead to serious misinterpretation.

If vaccination of a woman of child-bearing age is contemplated, the following steps are indicated:

- 1) The woman should be tested for susceptibility to rubella by the HI test (See Rubella Immunity).
- If immune, she should be assured that vaccination is not necessary.
- 3) If susceptible, she may be vaccinated only if it is ascertained that she is not pregnant and if she understands that it is imperative for her to avoid becoming pregnant for the following 2 months. (To ensure this, a medically acceptable method for pregnancy prevention should be followed. This precaution also applies to women in the immediate post-partum period.) Additionally, she should be informed of the frequent occurrence of joint involvement (see above).

There is no evidence that live rubella virus vaccine given after exposure will prevent illness. There is, however, no contraindication to vaccinating children already exposed to natural rubella.

There is no contraindication to vaccination of individuals with pre-existing antibody.

Precautions in Using Live Rubella Virus Vaccine

Pregnancy: Live rubella virus vaccine is contraindicated. (See Recommendations for Vaccine Use.)

Altered Immune State: Attenuated rubella virus infection might be potentiated by severe underlying diseases, such as leukemia, lymphomas, or generalized malignancy, and when resistance has been lowered by therapy with steroids, alkylating drugs, antimetabolites, or radiation. Such patients should not be given live rubella virus vaccine.

Severe Febrile Illness: Vaccination should be postponed until the patient has recovered.

Hypersensitivity of Vaccine Components: Rubella vaccine should theoretically not be given to children clearly sensitive to the tissue substrates or other components of the vaccine. To date, there have been no documented reports of serious hypersensitivity reactions to rubella vaccine.

Simultaneous Administration of Live Rubella Virus Vaccine and Other Live Virus Vaccines.

Simultaneous administration of live rubella virus vaccine and other live virus vaccines is not recommended as a routine practice until results of controlled clinical investigations are available. Until then, it is recommended that rubella vaccination be separated by at least 1 month from administration of other live virus vaccines.

SURVEILLANCE

Careful surveillance of rubella infection is particularly important with the general use of vaccine. Emphasis should be placed upon improved diagnosis and reporting of rubella, of the congenital rubella syndrome, and of complications of the disease and the vaccine. Competent laboratory investigation of all infants with birth defects suspected of being due to rubella is essential. It will likewise be important to observe patterns of vaccine use and determine its effectiveness.

Morbidity and Mortality Weekly Report

TABLE III. CASES OF SPECIFIED NOTIFIABLE DISEASES: UNITED STATES

FOR WEEKS ENDED

AUGUST 29, 1970 AND AUGUST 23, 1969 (34th WEEK)

AREA AREA Colore Color							·	- WEE				
AREA 1970			l						HEPATITIS		MALA	RIA
NINTED STATES	AREA	GITIS	LOSIS	THERIA		_		Serum	Infec	tious		
NEW ENCLAND.		1970	1970	1970	1970	1969	1970	1970	1970	1969	1970	
Mathemaphire:	UNITED STATES	302	3	28	35	26	6	167	1,173	880	62	2,239
Mariachusetts 29 24 1 5 5	NEW ENGLAND	10	_	_	3	1	1 1	12	124	83	2	
Vermont	Maine	_	_	_	I		ł I		29			
Messachusettes. 4 3 1 - 4 4 47 31 - 33 Rhode Island. 6 3 1 - 4 4 19 8 - 8 Cennecticut 1 1 3 21 13 - 10 New York City. 63 1 1 1 3 32 4 57 27 New York DeStare. 1 - 2 2 - 1 1 3 77 20 2 78 New York DeStare. 1 - 2 2 - 1 3 45 32 2 65 New Jersey. 1 10 - 1 2 - 13 47 32 35 3 66 New Jersey. 1 10 - 1 2 - 13 47 32 2 65 New Jersey. 1 10 - 1 2 - 13 45 32 2 65 New Jersey. 1 10 - 1 2 - 13 45 32 2 65 New Jersey. 1 10 - 1 9 6 - 4 38 30 1 2 26 New Jork DeStare. 1 1 - 2 1 1 6 9 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			ì	1	1		1	-				
MIDDLE ATLANTIC. 75					i	ŧ .			-			33
MIDDLE ATLANTIC. 75 9 3 - 65 201 144 7 239 New York City. 63 - 1 1 - 38 42 57 - 26 New York City. 63 - 1 1 - 38 42 57 - 26 New York City. 63 - 1 2 - 1 37 38 42 57 - 26 New York City. 63 1 1 - 38 42 57 - 26 New York City. 63 1 2 - 1 37 38 25 26 New York City. 63 1 2 - 1 37 77 20 2 2 78 New York City. 63 1 2 - 1 3 77 20 2 2 78 New York City. 63 1 9 6 - 4 38 30 12 2 78 New York City. 63 1 9 6 - 4 38 30 12 2 33 New York City. 63 - 1 9 6 - 4 38 30 12 2 33 New York City. 63 - 1 9 6 - 4 38 30 12 2 33 New York City. 63 - 1 9 6 - 4 38 30 12 2 33 New York City. 64 1 35 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 1 3 3 36 1 30 15 New York City. 64 2 - 3 2 1 13 168 105 7 417 New York City. 64 2 - 3 2 1 13 168 105 7 417 New York City. 64 2 - 3 2 1 13 168 105 7 417 New York City. 64 2 - 3 2 1 13 168 105 7 417 New York City. 64 1 3 1 - 4 43 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				l	3	_				_		
New York, Up-State. 1 2 1 37 38 42 57 - 27 8 New York, Up-State. 1 2 1 37 35 3 69 New Jercey. 1 10 1 2 - 13 45 32 2 65 New Jercey. 1 10 1 2 - 13 77 20 2 78 New Jercey. 1 10 1 2 - 13 77 20 2 78 New Jercey. 1 10 1 2 - 13 77 20 2 78 New Jercey. 1 10 1 2 - 13 77 20 2 78 New Jercey. 1 1 1 2 - 13 77 20 2 78 New Jercey. 1 1 1 2 - 13 77 20 2 78 New Jercey. 1 1 1 2 - 13 77 20 2 78 New Jercey. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Connecticut	-	_	-	_	_	1	3	21	13	_	10
New JOYSE, Up-States 10 - 2 2 - 13 437 35 3 6 99 New JOSES, 10 10 - 1 2 - 13 457 35 32 2 65 Pennsylvania. 1 - 5 - 1 2 - 13 457 32 2 6 55 Pennsylvania. 1 - 5 - 1 2 2 2 13 457 32 2 6 55 Pennsylvania. 1 - 5 - 1 3 457 32 2 6 6 Pennsylvania. 1 - 1 - 1 3 46 - 1 3 77 20 2 78 8 9 9 9 1 1 1 - 1 1 1 1 1 1 1 1 1 1 1 1 1		75	_	_	9	3	_	65	201	144	7	
New Jergey, 5		ı		1								
Pennsylvania.		ı		l		l						
Ohto 15		Ι.		l				_				78
Ohto 15	FACT NODTH CENTRAL	24		,	12	12	,	20	170	110		126
Indidama		I		1		I						26
Michigan	Indiana	2		-	-	· 1		1	16	9		
## ## ## ## ## ## ## ## ## ## ## ## ##				1		l			1			
WEST NORTH CENTRAL.		l		1		l						-
Minesota			_					_				202
Missouri					_	l						
North Dakotas				1		l						
South Dakota.				1								
Nebraska				t .								
SOUTH ATLANTIC.												
Delaware		-	_	_	-	-	-	2	8	3	15	139
Delaware	SOUTH ATLANTIC	46	2		3	2	1	13	168	105	. 7	
Dist. of Columbia. 5		-										
Dist. of Columbia. 5				1								
West Virginia 2 - - - - - 2 2 1 169 North Carolina 1 - - - - - 3 2 - 34 Georgia - - - - - - - 3 2 - 64 Florida 13 - - - - - - 27 55 - 42 EAST SOUTH CENTRAL 8 - 2 5 3 1 - 49 61 5 160 Kentucky 2 - - 1 - - 16 30 5 132 Tennessee 3 - - 4 2 1 - - 160 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 <td></td> <td>55</td>												55
South Carolina.		_		1								
South Carolina								_			_	34
Florida							I					63
Note							1	1			_	42
Kentucky. 2 - - 1 - - - 16 30 5 132 Tennessee. 3 - - 4 2 1 - 26 22 - 18 Alabama. 1 - 2 - 1 - - 4 3 - 18 Mississippi. 2 - - - - - 1 - - 18 6 - 10 WEST SOUTH CENTRAL. 23 - 24 1 - - 11 85 54 5 406 Arkansas. - - 1 - - 5 10 10 1 69 9 9 - 29 9 - 29 9 - 29 9 - 26 6 4 35 4 303 303 3 187 2 187 187 187 187 187 187 187 188 188 188 188 188<	FACT COUTH CENTRAL			,	_	,	1	_	. 10	61	5	160
Tennessee									- 1			132
Alabama		3	-		4		1	-	i			18
WEST SOUTH CENTRAL 23 - 24 1 11 85 54 5 96 Arkansas 1 2 25 Louisiana.*. 17 5 100 10 1 69 Oklahoma 2 5 100 10 1 69 Texas 4 - 24 6 64 35 4 MOUNTAIN 24 1 1 1 55 37 2 187 Montana 1 1 1 4 2 3 Idaho 1 1 4 2 3 Idaho 1 1 4 2 3 Idaho 1 1 2 1 2 3 Idaho 1 1 2 1 1 Nyoming 1 30 11 - 7 New Hexico 1 30 11 - 7 New Mexico 1 4 13 - 3 Utah 1 4 13 - 3 Utah 1 4 13 - 3 Utah 1 3 - 3 2 2 2 2 1 Nevada 1 3 2 2 2 1 Nevada 1 3 3 2 2 2 4 2 2 3 3 4 3 4 3 4 3 4 3 4 3												
Arkansas.	mississippi		-	_	_	_	_	_	3		_	406
Louisiana.*		23	-	24		1	-1 V	11		54		9
Oklahoma 2 - - - - 9 9 - 303 Texas 4 - 24 - - - 6 64 35 4 303 MOUNTAIN 24 - - 1 1 - 1 55 37 2 187 Montana 1 - - 1 - - 1 4 2 3 Idaho - - - - - - - 1 4 2 3 Wyoming - - - - - - - - - 158 Colorado - - - - - - 1 30 11 - 7 New Mexico - - - - - - 1 3 - 3 1 - - - - - - - - - - - - - - - <		17	_	_			_	5		10		
MOUNTAIN			_	1			-					203
MOUNTAIN 24 - - 1 - - 1 4 2 10 Montana 1 - - 1 - - 1 4 2 3 Howaing -	Texas	4	-	24	-	-	-	6	64	35	4	
Montana. 1 - - 1 - - 1 4 2 3 Idaho. - - - - - 2 1 -	MOUNTAIN	24	_	_	1	1	_	1	55	37	2	
Wyoming. - - - - - 158 Colorado. - - - - - 1 300 11 - 7 New Mexico. - - - - - - 26 - 6 Arizona. 23 - - - - 14 13 - 3 Utah. - - - - - 14 13 - 3 Nevada. - <	Montana.		- 1	_		_	· I	-	1	4	2	
Colorado.							ı					-
New Mexico		l l		_			_		_			158
Utah. - <td>New Mexico</td> <td>-</td> <td>-</td> <td>_ </td> <td>_</td> <td>-</td> <td></td> <td>_</td> <td>2</td> <td>6</td> <td></td> <td></td>	New Mexico	-	-	_	_	-		_	2	6		
Nevada				_								
PACIFIC. 78 1 3 - 33 285 248 13 435		,		_								_
PACIFIC						_					4.5	435
Oregon - - - - - 1 22 23 - 282 California 61 - - 1 3 - 32 244 206 9 1 Alaska 15 - - - - - - 1 1 - 95 Hawaii 1 - - - - - - 3 4 - 9 Puerto Rico.* - - - - - 8 38 20 - -				_								43
California		- <u>-</u>										
Hawaii	California		1	_				32	244	206		1
Puerto Rico.† 8 38 20 - 9			_	-		-	_	_				95
Tuerto naco	nawaii						- -					9
		-				l .	I		1			لتسي

^{*} Delayed Reports: Aseptic Meningitis: La. Delete 1 Hepatitis, Serum: N.J. Delete 1, P.R. 1 Hepatitis, Infectious: N.J. Delete 3, P.R. 1

Morbidity and Mortality Weekly Report

TABLE III. CASES OF SPECIFIED NOTIFIABLE DISEASES: UNITED STATES

FOR WEEKS ENDED

AUGUST 29, 1970 AND AUGUST 23, 1969 (34th WEEK) - CONTINUED

	MEA	SLES (Rube	ola)	MENINGO	COCCAL INF	ECTIONS,	MUN	rps	POI	LIOMYELITI	s
AREA		Cumul	ative		Cumula	itive		Cum.	Total	Paral	
	1970	1970	1969	1970	1970	1969	1970	1970	1970	1970	Cum. 1970
UNITED STATES	186	39,235	20,001	37	1,808	2,300	620	74,476	_	_	18
NEW ENGLAND	7	879	1,087	1	7 9	82	42	8,815	_	_	_
Maine	3	204	1,007	<u>.</u>	, š	6	5	673	_	_	_
New Hampshire	_	50	238	_	8	2	1	326	_	_	_
vermont	_	8	3	_	7	_	ż	585	_	_	_
Massachusetts	4	416	212	1	35	33	11	2,781	_	_	_
Khode Island	_	118	23	_	5	10	9	1,472	_	_	_
Connecticut	-	83	603	-	21	31	14	2,978	-	-	-
MIDDLE ATLANTIC	22	4,798	7,430	12	331	377	50	7,430	_	-	_
"ew York City	5	856	4,876	7	81	73	41	2,702	-	-	_
New York, Up-State	11	266	593	2	66	68	NN	NN	- [-	_
New Jersey	3	1,701	882	-	126	153	3	2,055	-	-	-
Pennsylvania	3	1,975	1,079	3	58	83	6	2,673	-	-	_
EAST NORTH CENTRAL	35	9,708	2,119	5	202	314	180	19,820	-	-	2
Ohio.	13	3,795	369	2	80	118 35	33	3,569	-	-	-
Indiana.	7	267	466	1 1	20 44	35 44	11 12	1,769	_	_	_
Illinois. Michigan	9	3,039 1,699	485 240	1	49	95	28	1,721 4,905	_	_	1
Wisconsin	6	908	559	<u>-</u>	9	22	96	7,856	_	_	i
WEST NORTH CENTRAL	25	3,841	515	1	93	118	13	3,712	_	_	1
"Innesota		3,841	6	<u>'</u>	13	25	2	346			
Towa.	24	1,128	329	_	12	16	3	2,273	_	_	_
"1SSourf	- i	1,267	22	1	55	51	6	264	_	_	1
Worth Dakota	_	318	12	_ ;	3	1	2	275	_	_	_
South Dakota	_	93	3	_ '	_	1	_	40	_	_	_
"ebraska	_	924	136	_	5	9	_	378	_	_	_
Kansas	-	73	7	-	5	15	-	136	-	-	-
SOUTH ATLANTIC	17	7,127	2,473	6	372	398	90	8,554	_	_	■ 1
Delaware	2	260	373	_	3 . 3	8	5	295	_	_	
"dryland"	_	1,375	74	_	34	36	14	917	_		_
of Columbia	_	343	– 1	_	3	8	2	186	_		_
'Irginia.	_	1,971	883	1	40	50	20	1,972	- 1	_	_
"EST Virginia	_	308	191	2	10	18	25	2,079	-	-	1
"orth Carolina	6	856	313	1	76	67	NN	NN	-	_	_
Carolina	8	593	116	_	44	54	10	830	_	_	_
Georgia. Florida.	1	1,407	522	2	32 130	70 87	14	2,275	=	_	_
	_	'				440		'			
EAST SOUTH CENTRAL	5	1,304	107	1	133	142	32	4,321	-	_	_
	4	752	63	-	45	50 53	3	1,567	_	_	_
Tennessee	1	373 91	17	_	58 21	24	26	2,452	_	_	I
Alahama. Mississippi	_	88	23	1	9	15	_	46	_	_	_
WEST SOUTH CENTRAL	34	7,485	4,426	7	244	311	63	7,155	_	_	14
	J4	30	16	í	21	29	- 03	117	-	_	
Louistana	_	92	120	2	61	80	_	27	_	_	_
	1	443	136	_	19	30	_	2,391	-	_	_
	33	6,920	4,154	4	143	172	63	4,620	-	-	14
MOUNTAIN	20	1,499	834	1	37	43	66	3,397	_	_	_
Montana. Idaho	7	60	16	<u>.</u>	i	8	31	716	_	-	-
	_	35	89	_	6	8	_	87	_	_	_
	-	11	7 <u>~</u>	_	1	-	2	34	_	_	_
Colorado.	-	176	140	-	12	7	9	1,085	-	_	=
	8	198	242	1	1	6	10	656	-	-	-
	4	965	338	-	14	10	14	695	-	-	-
Utah. Nevada.	1 -	33 21	8	_	2 -	2 2	I I	124	_	_	_
PACIFIC				_	247	E 4 F	,,	11 272			i
PACIFIC	21	2,594 523	1,010 59	3 -	317 43	515 54	84	11,272 4,205	_	_	_
regon	2	228	198	1	25	15	6	978	– i	_	_
Californ	19	1,525	708	2	247	425	39	4,624	_ '	_	-
Alaska.	-	136	8	_	-	11	1	379	-	_	-
***********		182	37		2	10	27	1,086		-	
Virgim Islands	2	879	1,419	1	5	19	19	697	_	_	_
Sile Tol.	_	6	40	_	1	_	-	1	_	_	I -

Morbidity and Mortality Weekly Report

TABLE III. CASES OF SPECIFIED NOTIFIABLE DISEASES: UNITED STATES FOR WEEKS ENDED

AUGUST 29, 1970 AND AUGUST 23, 1969 (34th WEEK) - CONTINUED

AREA	RUBEI	LLA	TETAN	NUS	TULARI	EMIA .	TYPHO FEVI		TYPHUS TICK-	BORNE	RABIE:	
	1970	Cum. 1970	1970	Cum. 1970	1970	Cum. 1970	1970	Cum. 1970	1970	Cum. 1970	1970	Cum. 1970
UNITED STATES	201	48,786	2	75	3	94	11	183	12	273	53	2,047
NEW ENGLAND	20	2,391	-	3	-	1	_	7	-	-	3	71 25
Maine New Hampshire	3	385 150	_	_	_	_	-	_		_	1 -	1
Vermont	-	49	- :		- 1	- 1	_	_	_	-	1	40
Massachusetts	13 3	1,161 99	_ :	2	_	1	_	5	-	-	1	2
Rhode Island Connecticut	1	547	_	1	_	_	_	2	_	_	_	2
MIDDLE ATLANTIC	14	3,906	_	6	1	2	1	42	1	11	5	187
New York City	5	574	-	3	-	-	-	11	-	-	-	176
New York, Up-State	3 5	409 853	<u> </u>	_ 2		1 -	1	16 7	_	6	5 	1/0
New Jersey	1	2,070	_	1	1	1	_	8	1	2 3	_	11
EAST NORTH CENTRAL	46	10,159	_	13	1	18	_	25	_	6	8	169
Ohio	3	2,013	-	1	-	2	-	10	-	5	-	44 14
Indiana	19 2	1,815	_	5	_	12	_	1 5		- 1	4	55
Illinois	12	1,685 2,636	_	4	_	2	_	8	_	1	1	17
Wisconsin	10	2,010	_	_	1	2	-	1	-	_	3	39
WEST NORTH CENTRAL	9	3,264	_	4	_	24	-	7	_ '	2	9	383 75
Minnesota	_ 5	117	-	1	-	-	-	1	-	- 1	4	69
Iowa. Missouri.	1	1,999	_	1	_	21	_	1	-	2	3 1	71
North Dakota.	3	144	_	_	_	1	_	2	-		<u>-</u>	26
South Dakota	-	1	-	1	_	1	_	-	-	- 1	-	60
Nebraska	_	543 55	_	_	<u>-</u>	1	_	2	-	-	-	76
Kansas	_		_		_			_	-	-	1	421
SOUTH ATLANTIC	15 _	6,170 41	1	19	_	9	5	29	10	187	8	421
Delaware	1	312	_	_		_	2	8	_	19	_	1
Dist. of Columbia	_	19	_	1	_	-	1	1	-		-	176
Virginia	2	681	-	-	_	1	_	4	6	51	_	111
West Virginia North Carolina	8	1,264 39	_	3	_	4	_	2	3	5 68	3	1
South Carolina	2	630	_	1 1	_	_	_	_	1 1	32	_	-7
Georgia	_	2 4 2 2	-	2	_	3	1	8	-	8	2	74 58
Florida	2	3,184	1	12	-	1	1	6	_	-	3	163
EAST SOUTH CENTRAL	23	2,577	1	9	1 –	4 1	2	14	_	30	3	89
Kentucky Tennessee	4 14	913 1,316	1	1 3	1 1	3	1	1 8	_	3 18	1 2	48
Alabama	5	270	_	5		_	1	5	-	6	_	25 1
Mississippi	_	78	-	-	_	-	-	-	-	3	-	1.45
WEST SOUTH CENTRAL	23	8,638	-	12	_	25	_	14	1	30	11	360 63
ArkansasLouisiana	_	34 148	_	3	_	10 4	_	3		5 1	1	54
Oklahoma, *	_	807	_		-	8	_	1 1		19	i	72
Texas	23	7,649	_	6	_	3	_	9	1	5	8	171
MOUNTAIN	10	1,942	_	_	_	5	2	11	_	6	3	62
Montana	-	315	-	-	-	-	-	1	-	1	-	
Idaho	_	181 133	_	_	_	_	_	_	_	2	1	3
Wyoming	4	393	_	_	_	_ =	1	3	_	2		30
New Mexico	2	205	_	-	_	_	_	5	_	_	-	11
Arizona	3	553	-	-	-	_	1	1	-	-	-	1
Utah Nevada	1	162	_	_	_	5 -	_	1 -	_		2	1
PACIFIC	41	9,739	_	9	_	6	1	34	_	1	3	231 8
Washington	4	4,597	_	2	_	2		4	_	_	1	1
Oregon	12	830	-	3	_	1	1	1	-	-	-	222
California	24	4,015	_	4	_	3	_	26	_	1	2	
Alaska Hawaii	1	94 203	_	_	_	_	-	2	_	<u>-</u>		
Puerto Rico		26	1	7	_	_	1	4		_	-	35
Virgin Islands	_			<u>-</u>	_	_	_	-	_		-	-

^{*} Delayed Reports: Typhoid Fever: Okla. 1

Week No. TABLE IV. DEATHS IN 122 UNITED STATES CITIES FOR WEEK ENDED AUGUST 29, 1970

(By place of occurrence and week of filing certificate. Excludes fetal deaths)

	All Ca	uses		Had an		All Ca	11508		
Amon			Pneumonia and	Under 1 year	ll		uses	Pneumonia and	Under 1 year
Area	All Ages	65 years and over	Influenza	A11	Area	All Assa	65 years	Influenza	All
		and over	All Ages	Causes		Ages	and over		Causes
NEW ENGLAND:	673	403	40	7.5		4 220	641	40	
Boston, Mass	673 214	403 117	13	35 12	SOUTH ATLANTIC:	1,238 140	641 67	49 2	64
Bridgeport, Conn	32	23	5	1	Atlanta, Ga Baltimore, Md	235	113	5	1.
Cambridge, Mass	30	19	4	i	Charlotte, N. C	76	29	_	
Fall River, Mass	32	24	2			79	42	_ 1_	
Hartford, Conn	58	36	2	3	Jacksonville, Fla Miami, Fla	110	64	2	
Lowell, Mass	19	15	ī	2	Norfolk, Va	52	24	5	
Lynn, Mass	19	11	_		Richmond, Va	76	44	10	
New Bedford, Mass	29	18	2	1	Savannah, Ga	43	22	3	_ :
New Haven, Conn	67	28	3	10	St. Petersburg, Fla	92	76	6	
Providence, R. I	51	34	5	1 1	Tampa, Fla	69	38	5	
Somerville, Mass	10	و ا	_	127	Washington, D. C	213	96	8	1
Springfield, Mass	39	26	4	1	Wilmington, Del	53	26	2	
Waterbury, Conn	27	12		2	Wilmington, Bel.	•		570	
Worcester, Mass	46	31	1	3	EAST SOUTH CENTRAL:	635	348	35	2
		1	'		Birmingham, Ala	86	39	2	_
IDDLE ATLANTIC:	3,249	1,887	112	150	Chattanooga, Tenn	48	32	5	
Albany, N. Y	54	32	1	4	Knoxville, Tenn	37	18	4	20
Allentown, Pa	29	16	3	1	Louisville, Ky	138	73	15	
Buffalo, N. Y	144	71	3	14	Memphis, Tenn	156	87	1	3
Camden, N. J	52	28	3	2	Mobile, Ala	32	14	2	
Elizabeth, N. J	18	11	Ĭ		Montgomery, Ala	40	26	4	
Erie, Pa	41	23	4	2	Nashville, Tenn	98	59	2	
Jersey City, N. J	57	30	6	2					}
Newark, N. J	70	34	-	4	WEST SOUTH CENTRAL:	1,197	597	38	9
New York City, N. Yt	1,688	987	58	71	Austin, Tex	39	24	5	
Paterson, N. J	37	27	2	1	Baton Rouge, La	35	15	2	
Philadelphia, Pa	498	278	7	28	Corpus Christi, Tex	45	20	-	1
Pittsburgh, Pa	182	102	7	8	Dallas, Tex	161	72	1	
Reading, Pa	39	27	2	77.0	El Paso, Tex	51	17	3	1
Rochester, N. Y	122	75	4	7	Fort Worth, Tex	93	56	8	
Schenectady, N. Y	29	23	3	-	Houston, Tex	220	107	1	1
Scranton, Pa	32	22	1	-	Little Rock, Ark	70	38	1	
Syracuse, N. Y	73	45	· -	3	New Orleans, La	163	69	4	1
Trenton, N. J	30	17	2	2	Oklahoma City, Okla	77	40	1 1	
Utica, N. Y	28	20	5	-	San Antonio, Tex	122	66	3	1
Yonkers, N. Y	26	19	1 	1	Shreveport, La	49	30	1	
		İ		1	Tulsa, Okla	72	43	8	
AST NORTH CENTRAL:	2,474	1,343	68	144	,			1	
akron, Ohio	62	36		3	MOUNTAIN:	461	261	10	1
Canton, Ohio	31	20	1	1	Albuquerque, N. Mex	49	21	2	
Chicago, Ill	650	328	21	33	Colorado Springs, Colo.	24	15	1	
Uncinnati. Ohio	171	104	1	6	Denver, Colo	124	78	3	
Cleveland, Ohio	194	92	3	22	Ogden, Utah	15	9	2	
Columbus, Ohio	136	66		16	Phoenix, Ariz	123	65	2	
Dayten, Ohio	84	49	1	3	Pueblo, Colo	12	7	-	1
Detroit, Mich	335	180	14	12	Salt Lake City, Utah	55	27	-	l
Evansville, Ind.	35	22	2	2	Tucson, Ariz	59	39	_	
'11nt, Mich	57	33		5	· ·				1
Fort Wayne, Ind	50	27	4	5	PACIFIC:	1,547	930	23	1 4
oary, Ind	26	10	l i	1	Berkeley, Calif	25	16	-	
Grand Rapids, Mich	34	25	i	2	Fresno, Calif	54	24	1	1
""ulanapolis Ind	148	75	2	7	Glendale, Calif	29	23	_	
"Idd 1son. Wis	59	31	6	8	Honolulu, Hawaii	61	31	1	
""IWaukee Wis	127	73	2	2	Long Beach, Calif	90	59	1	
'euria, Ill	40	20	1	4	Los Angeles, Calif	424	260	8	
"Ockford T11	33	21	1	-	Oakland, Calif	84	47	2	
South Bend Ind	45	32	4	1	Pasadena, Calif	31	24	1	
Toledo. Objorgania	103	69	2	7	Portland, Oreg	127	71	1	
Youngstown, Ohio	54	30	1	4	Sacramento, Calif	62	35	1	
		1	l		San Diego, Calif	107	63	[1	1
EST NORTH CENTRAL:	797	458	24	45	San Francisco, Calif	204	128	4	I
	64	38	4	4	San Jose, Calif	31	19	~_	1
Tuch Minn	35	22	5	1	Seattle, Wash	137	73	1	1
Tusas City Vanc	38	22	-	7	Spokane, Wash	44	29	-	1
Ma and and and and and and and and and an	119	69	3	6	Tacoma, Wash	37	28	1	1
TallCoin Nobe	28	21	1	-			 		\vdash
"Tuneanolic Minn	99	56	i	3	Total	12,271	6,868	399	6
Moha	71	39	1	4		•	 	 	-
LOuis Mo	235	127	5	12	Expected Number	11,925	6,804	336	4
PAul Winn	75	50	2	2			· · · · ·	 	
Wichita, Kans	33	14	2	6	Cumulative Total (includes reported corrections		i	l	l
	23	l ''	1 -		for previous weeks)	443,047	252,971	17,712	20,8
- L			 				<u> </u>		
Vegas, Nev.*	18	8	4	2	*Mortality data are being collected				
o -, nev."	1.0		, a		table, however, for statistical reason the total, expected number, or cumul				

INTERNATIONAL NOTES **CHOLERA**

During the past week, the World Health Organization (1) reported cholera or changes in regulations concerning cholera for the following countries according to Sections 1, 3 and 4* of its Daily Epidemiological Radiotelegraphic Bulletin: Burma, India, Indonesia, Republic of Korea, Lebanon, Nepal, East Pakistan, the Philippines, Trucial Oman -Dubai, the USSR, and Vietnam were listed under Section 1; Israel and Libya were listed under Section 3; and Guinea in West Africa was listed under Section 4.

According to a recent press report from WHO, Geneva, Vibrio cholerae El tor strain has been isolated from persons with diarrheal illness in Guinea by a team of WHO investigators (2). Additional press accounts reported cholera in Iran, Iraq, Jordan, Saudi Arabia, Syria, Tunisia, Turkey, and the United Arab Republic.

(Reported by the Foreign Quarantine Program, CDC.)

References:

- 1. World Health Organization Weekly Epidemiological Record 45(35), Aug. 28, 1970
- 2. The New York Times, Sept. 2, 1970

*CLASSIFICATION SYSTEM:

- Section 1 cases of quarantinable diseases in cities adjacent to a port or airport including the port or airport area unless otherwise indicated.
- Section 3 (a) cases of quarantinable diseases of particular epidemiological significance in areas which are not port or airport cities; (b) imported or transferred case(s) of a quarantinable disease in a non-infected port or airport city.
- Section 4 important new information related to the International Sanitary Regulations not included in Sec-

THE MORBIDITY AND MORTALITY WEEKLY REPORT, WITH A CIRCULA^{*} Tion of 21,000 is published at the center for disease control, ATLANTA, GEORGIA.

DIRECTOR, CENTER FOR DISEASE CONTROL DIRECTOR, EPIDEMIOLOGY PROGRAM DAVID J. SENCER, M.D. PHILIP S. BRACHMAN, M.D.

FDITOR MANAGING EDITOR MICHAEL B. GREGG, M.D.

IN ADDITION TO THE ESTABLISHED PROCEDURES FOR REPORTING MORBIDITY AND MORTALITY, THE CENTER FOR DISEASE CONTROL WELCOMES ACCOUNTS OF INTERESTING OUTBREAKS OR CASE INVESTIGATIONS WHICH ARE OF CURRENT INTEREST TO HEALTH OFFICIALS AND WHICH ARE DIRECTLY RELATED TO THE CENTER FOR DISEASE CONTROL, SUCH COMMUNICATIONS SHOULD BE ADDRESSED TO:

CENTER FOR DISEASE CONTROL
ATTN: THE EDITOR
MORBIDITY AND MORTALITY WEEKLY REPORT ATLANTA, GEORGIA 30333

NOTE: THE DATA IN THIS REPORT ARE PROVISIONAL AND ARE BASED ON WEEKLY TELEGRAMS TO THE CDC BY THE INDIVIDUAL STATE HEALTH DEPARTMENTS: THE REPORTING WEEK CONCLUDES AT CLOSE OF BUSINESS ON FRIDAY; COMPILED DATA ON A NATIONAL BASIS ARE OFFICIALLY RELEASED TO THE PUBLIC ON THE SUCCEEDING FRIDAY.

OFFICIAL BUSINESS

HEALTH SERVICES AND MENTAL HEALTH ADMINISTRATION CENTER FOR DISEASE CONTROL ATLANTA, GEORGIA 30333

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE PUBLIC HEALTH SERVICE

BRARY
MMUNICABLE DISEASE CENTER

U.S. DEPARTMENT OF H.E.W. POSTAGE AND FEES PAID

